# Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

> **NCT07583342** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Northwell Health** · enrollment: 15 (estimated)

## Conditions studied

- Acute Pancreatitis (AP)
- Enhancing Enteral Nutrition Tolerance

## Interventions

- **DEVICE:** RELiZORB digestive enzyme (immobilized lipase) cartridge

## Key facts

- **NCT ID:** NCT07583342
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-08
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07583342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07583342, "Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT07583342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*